{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-020039","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.265298+00:00","generated_at":"2026-05-25T15:22:50.626378+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alumis and ACELYRIN reaffirm all-stock merger; pro forma cash ~$737M","bullets":["Alumis and ACELYRIN reaffirm commitment to merge in an all-stock transaction expected to close Q2 2025.","Pro forma cash of ~$737M as of Dec 31, 2024 provides runway into 2027.","Alumis had ~$289M cash, ACELYRIN ~$448M (preliminary, each as of Dec 31, 2024).","Combined portfolio includes ESK-001 (psoriasis, lupus), lonigutamab (thyroid eye disease), A-005 (multiple sclerosis).","Transaction subject to stockholder approvals and customary closing conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-020039","json":"https://secwatch.observer/filing/0001104659-25-020039.json","markdown":"https://secwatch.observer/filing/0001104659-25-020039.md","text":"https://secwatch.observer/filing/0001104659-25-020039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925020039/0001104659-25-020039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925020039/tm258190d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T15:22:50.626378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}